First ever chlamydia vaccine has reached phase I clinical trial
The journal The Lancet Infectious Diseases publishes article on the first ever chlamydia vaccine to reach a phase I clinical trial
Recently the first ever chlamydia vaccine reached phase 1 clinical trial. The study was published by The Lancet Infectious Diseases and showed the vaccine to be safe and able to provoke an immune response. The vaccine (CTH522) has the potential to target the ocular serovar B, and efforts to expand the use of CTH522 against ocular infections in a key objective of TracVac consortium.
The article can be found on the Lancet website: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30279-8/fulltext